Rare Disease Clinical Trial Feasibility Tool
Rare Disease Management announced its rare disease clinical trial feasibility tool
Rare Disease Management (RDM)
, a clinical development company, based in Wilmington, NC focusing primarily on orphan and rare diseases, announced its rare disease clinical trial feasibility tool that enables pharmaceutical, biotech and CRO clients to best identify the top investigators in orphan and rare diseases. The tool— ExpertSense—was developed by RDM in collaboration with the Technical University of Denmark Bioinformatics team. That team was also responsible for the introduction of FindZebra, a investigator tool that helps give rare disease investigators a hypothesis for rare diseases.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
